Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

Phase 1/2 Active not recruiting 612 enrolled Clover Biopharmaceuticals AUS Pty

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).

Timeline

Start: 2025-06-18
Primary completion: 2028-03
Completion: 2028-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	SCB-1019T	Vaccine	—	—
Subject	SCB-1022	Vaccine	—	—
Subject	SCB-1033	Vaccine	—	—

Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

Summary

Timeline

Drugs

Indications